Pathogenesis of liver cirrhosis

World Journal of Gastroenterology

Volumn 20, Issue 23, 2014, Pages 7312-7324

  Zhou, Wen Ce ^a   Zhang, Quan Bao ^b   Qiao, Liang ^c  

^a LANZHOU UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Animal model; Cirrhosis; Cytokine; Hepatic stellate cells; MiRNA; Pathogenesis; Therapy

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; ALPHA TOCOPHEROL; AZATHIOPRINE; BETA INTERFERON; CELECOXIB; COLCHICINE; ENTECAVIR; GAMMA INTERFERON; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 6; LAMIVUDINE; MICRORNA; PEGINTERFERON ALPHA; PLATELET DERIVED GROWTH FACTOR; RAPAMYCIN; RIBAVIRIN; TAURINE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULOTROPIN; AUTACOID; CYTOKINE;

ALTERNATIVE MEDICINE; APOPTOSIS; ARTICLE; CELL ACTIVATION; FIBROGENESIS; GENE THERAPY; HUMAN; KUPFFER CELL; LIVER CELL; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER PROTECTION; LIVER REGENERATION; LIVER SINUSOIDAL ENDOTHELIAL CELL; MOLECULARLY TARGETED THERAPY; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; SIGNAL TRANSDUCTION; STELLATE CELL; ANIMAL; DISEASE MODEL; LIVER; METABOLISM; PATHOLOGY; RISK FACTOR;

ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION MEDIATORS; LIVER; LIVER CIRRHOSIS; MICRORNAS; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84902668983     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i23.7312     Document Type: Article

References (199)

1. Melato M, Mucli E. Something new in liver cirrhosis epidemiology. Lancet 1989; 2: 395-396 [PMID: 2569588 DOI: 10.1016/S0140-6736(89)90578-3]
2. Asrani SK, Larson JJ, Yawn B, Therneau TM, Kim WR. Underestimation of liver-related mortality in the United States. Gastroenterology 2013; 145: 375-82. e1-2 [PMID: 23583430 DOI: 10.1053/j.gastro.2013.04.005]
3. Qua CS, Goh KL. Liver cirrhosis in Malaysia: peculiar epidemiology in a multiracial Asian country. J Gastroenterol Hepatol 2011; 26: 1333-1337 [PMID: 21443669 DOI: 10.1111/ j.1440-1746.2011.06732.x]
4. Naveau S, Perlemuter G, Balian A. [Epidemiology and natural history of cirrhosis]. Rev Prat 2005; 55: 1527-1532 [PMID: 16255293]
5. Di Bisceglie AM. Natural history of hepatitis C: its impact on clinical management. Hepatology 2000; 31: 1014-1018 [PMID: 10733560 DOI: 10.1053/he.2000.5762]
6. Innes HA, Hutchinson SJ, Barclay S, Cadzow E, Dillon JF, Fraser A, Goldberg DJ, Mills PR, McDonald SA, Morris J, Stanley A, Hayes P. Quantifying the fraction of cirrhosis attributable to alcohol among chronic hepatitis C virus patients: implications for treatment cost-effectiveness. Hepatology 2013; 57: 451-460 [PMID: 22961861 DOI: 10.1002/ hep.26051]
7. Ganem D, Prince AM. Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med 2004; 350: 1118-1129 [PMID: 15014185 DOI: 10.1056/NEJMra031087]
8. Lv GC, Yao JM, Yang YD, Zheng L, Sheng JF, Chen Y, Li LJ. Efficacy of combined therapy in patients with hepatitis B virus-related decompensated cirrhosis. World J Gastroenterol 2013; 19: 3481-3486 [PMID: 23801842 DOI: 10.3748/wjg.v19. i22.3481]
9. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-283 [PMID: 19669255 DOI: 10.1007/s12072-008-9080-3]
10. Britton RS, Brown KE. Genetic hemochromatosis and Wilson's disease: role for oxidant stress? Hepatology 1995; 21: 1195-1197 [PMID: 7705796 DOI: 10.1002/hep.1840210445]
11. Olynyk JK, Trinder D, Ramm GA, Britton RS, Bacon BR. Hereditary hemochromatosis in the post-HFE era. Hepatology 2008; 48: 991-1001 [PMID: 18752323 DOI: 10.1002/hep.22507]
12. Camaschella C. Treating iron overload. N Engl J Med 2013; 368: 2325-2327 [PMID: 23758239 DOI: 10.1056/NEJMcibr1304338]
13. Dowling D. Screening for Wilson's disease in acute liver failure: a comparison of currently available diagnostic tests. Hepatology 2009; 50: 329 [PMID: 19333910 DOI: 10.1002/ hep.22949]
14. Deutsch M, Emmanuel T, Koskinas J. Autoimmune Hepatitis or Wilson's Disease, a Clinical Dilemma. Hepat Mon 2013; 13: e7872 [PMID: 23922560 DOI: 10.5812/hepatmon.7872]
15. Wu SJ, Yang YH, Tsuneyama K, Leung PS, Illarionov P, Gershwin ME, Chuang YH. Innate immunity and primary biliary cirrhosis: activated invariant natural killer T cells exacerbate murine autoimmune cholangitis and fibrosis. Hepatology 2011; 53: 915-925 [PMID: 21374662 DOI: 10.1002/hep.24113]
16. van Os E, van den Broek WW, Mulder PG, ter Borg PC, Bruijn JA, van Buuren HR. Depression in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 2007; 46: 1099-1103 [PMID: 17399846 DOI: 10.1016/ j.jhep.2007.01.036]
17. Popov Y. Mouse model of primary biliary cirrhosis with progressive fibrosis: are we there yet? Hepatology 2013; 57: 429-431 [PMID: 22815060 DOI: 10.1002/hep.25969]
18. Selmi C, Bowlus CL, Gershwin ME, Coppel RL. Primary biliary cirrhosis. Lancet 2011; 377: 1600-1609 [PMID: 21529926 DOI: 10.1016/S0140-6736(10)61965-4]
19. Poupon R, Chazouilleres O, Corpechot C, Chrétien Y. Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis. Hepatology 2006; 44: 85-90 [PMID: 16799997 DOI: 10.1002/hep.21229]
20. Lazo M, Hernaez R, Bonekamp S, Kamel IR, Brancati FL, Guallar E, Clark JM. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ 2011; 343: d6891 [PMID: 22102439 DOI: 10.1136/bmj.d6891]
21. Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865-873 [PMID: 17006923 DOI: 10.1002/hep.21327]
22. Tarantino G, Scopacasa F, Colao A, Capone D, Tarantino M, Grimaldi E, Savastano S. Serum Bcl-2 concentrations in overweight-obese subjects with nonalcoholic fatty liver disease. World J Gastroenterol 2011; 17: 5280-5288 [PMID: 22219597 DOI: 10.3748/wjg.v17.i48.5280]
23. Tarantino G, Colao A, Capone D, Conca P, Tarantino M, Grimaldi E, Chianese D, Finelli C, Contaldo F, Scopacasa F, Savastano S. Circulating levels of cytochrome C, gamma-glutamyl transferase, triglycerides and unconjugated bilirubin in overweight/obese patients with non-alcoholic fatty liver disease. J Biol Regul Homeost Agents 2011; 25: 47-56 [PMID: 21382273]
24. Anthony PP, Ishak KG, Nayak NC, Poulsen HE, Scheuer PJ, Sobin LH. The morphology of cirrhosis. Recommendations on definition, nomenclature, and classification by a working group sponsored by the World Health Organization. J Clin Pathol 1978; 31: 395-414 [PMID: 649765]
25. Wanless IR, Nakashima E, Sherman M. Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med 2000; 124: 1599-1607 [PMID: 11079009]
26. Ferrell L. Liver pathology: cirrhosis, hepatitis, and primary liver tumors. Update and diagnostic problems. Mod Pathol 2000; 13: 679-704 [PMID: 10874674 DOI: 10.1038/modpathol. 3880119]
27. Elsharkawy AM, Oakley F, Mann DA. The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis. Apoptosis 2005; 10: 927-939 [PMID: 16151628 DOI: 10.1007/s10495-005-1055-4]
28. Braet F, Wisse E. Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review. Comp Hepatol 2002; 1: 1 [PMID: 12437787 DOI: 10.1186/1476-5926-1-1]
29. Friedman SL. Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med 1993; 328: 1828-1835 [PMID: 8502273]
30. Lakner AM, Steuerwald NM, Walling TL, Ghosh S, Li T, McKillop IH, Russo MW, Bonkovsky HL, Schrum LW. Inhibitory effects of microRNA 19b in hepatic stellate cellmediated fibrogenesis. Hepatology 2012; 56: 300-310 [PMID: 22278637 DOI: 10.1002/hep.25613]
31. Oakley F, Meso M, Iredale JP, Green K, Marek CJ, Zhou X, May MJ, Millward-Sadler H, Wright MC, Mann DA. Inhibition of inhibitor of kappaB kinases stimulates hepatic stellate cell apoptosis and accelerated recovery from rat liver fibrosis. Gastroenterology 2005; 128: 108-120 [PMID: 15633128 DOI: 10.1053/j.gastro.2004.10.003]
32. Safadi R, Friedman SL. Hepatic fibrosis--role of hepatic stellate cell activation. MedGenMed 2002; 4: 27 [PMID: 12466770]
33. Gressner AM, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med 2006; 10: 76-99 [PMID: 16563223 DOI: 10.1111/j.1582-4934.2006. tb00292.x]
34. He Y, Huang C, Zhang SP, Sun X, Long XR, Li J. The potential of microRNAs in liver fibrosis. Cell Signal 2012; 24: 2268-2272 [PMID: 22884954 DOI: 10.1016/j.cellsig.2012.07.023]
35. Mori T, Okanoue T, Sawa Y, Hori N, Ohta M, Kagawa K. Defenestration of the sinusoidal endothelial cell in a rat model of cirrhosis. Hepatology 1993; 17: 891-897 [PMID: 8491454 DOI: 10.1002/hep.1840170520]
36. Straub AC, Stolz DB, Ross MA, Hernández-Zavala A, Soucy NV, Klei LR, Barchowsky A. Arsenic stimulates sinusoidal endothelial cell capillarization and vessel remodeling in mouse liver. Hepatology 2007; 45: 205-212 [PMID: 17187425 DOI: 10.1002/hep.21444]
37. Okanoue T, Mori T, Sakamoto S, Itoh Y. Role of sinusoidal endothelial cells in liver disease. J Gastroenterol Hepatol 1995; 10 Suppl 1: S35-S37 [PMID: 8589339 DOI: 10.1111/ j.1440-1746.1995.tb01794.x]
38. Oie CI, Appa RS, Hilden I, Petersen HH, Gruhler A, Smedsrød B, Hansen JB. Rat liver sinusoidal endothelial cells (LSECs) express functional low density lipoprotein receptorrelated protein-1 (LRP-1). J Hepatol 2011; 55: 1346-1352 [PMID: 21703209 DOI: 10.1016/j.jhep.2011.03.013]
39. Yokomori H, Oda M, Yoshimura K, Hibi T. Recent advances in liver sinusoidal endothelial ultrastructure and fine structure immunocytochemistry. Micron 2012; 43: 129-134 [PMID: 21906955 DOI: 10.1016/j.micron.2011.08.002]
40. Wisse E. An electron microscopic study of the fenestrated endothelial lining of rat liver sinusoids. J Ultrastruct Res 1970; 31: 125-150 [PMID: 5442603 DOI: 10.1016/ S0022-5320(70)90150-4]
41. Deaciuc IV, D'Souza NB, Fortunato F, Hill DB, Sarphie TG, McClain CJ. Alcohol-induced sinusoidal endothelial cell dysfunction in the mouse is associated with exacerbated liver apoptosis and can be reversed by caspase inhibition. Hepatol Res 2001; 19: 85-97 [PMID: 11137483 DOI: 10.1016/ S1386-6346(00)00087-5]
42. Bhunchet E, Fujieda K. Capillarization and venularization of hepatic sinusoids in porcine serum-induced rat liver fibrosis: a mechanism to maintain liver blood flow. Hepatology 1993; 18: 1450-1458 [PMID: 7694897 DOI: 10.1002/hep.1840180626]
43. Marvie P, Lisbonne M, L'Helgoualc'h A, Rauch M, Turlin B, Preisser L, Bourd-Boittin K, Théret N, Gascan H, Piquet-Pellorce C, Samson M. Interleukin-33 overexpression is associated with liver fibrosis in mice and humans. J Cell Mol Med 2010; 14: 1726-1739 [PMID: 19508382 DOI: 10.1111/ j.1582-4934.2009.00801.x]
44. Deleve LD, Wang X, Guo Y. Sinusoidal endothelial cells prevent rat stellate cell activation and promote reversion to quiescence. Hepatology 2008; 48: 920-930 [PMID: 18613151 DOI: 10.1002/hep.22351]
45. Xie G, Wang X, Wang L, Wang L, Atkinson RD, Kanel GC, Gaarde WA, Deleve LD. Role of differentiation of liver sinusoidal endothelial cells in progression and regression of hepatic fibrosis in rats. Gastroenterology 2012; 142: 918-927. e6 [PMID: 22178212 DOI: 10.1053/j.gastro.2011.12.017]
46. Kmieć Z. Cooperation of liver cells in health and disease. Adv Anat Embryol Cell Biol 2001; 161: III-XIII, 1-151 [PMID: 11729749 DOI: 10.1007/978-3-642-56553-3_7]
47. Kolios G, Valatas V, Kouroumalis E. Role of Kupffer cells in the pathogenesis of liver disease. World J Gastroenterol 2006; 12: 7413-7420 [PMID: 17167827]
48. Noda T, Mimura H, Orita K. Assessment of Kupffer cell function in rats with chronic liver injury caused by CCl4. Hepatogastroenterology 1990; 37: 319-323 [PMID: 2373463]
49. López-Navarrete G, Ramos-Martínez E, Suárez-Álvarez K, Aguirre-García J, Ledezma-Soto Y, León-Cabrera S, Gudiño-Zayas M, Guzmán C, Gutiérrez-Reyes G, Hernández-Ruíz J, Camacho-Arroyo I, Robles-Díaz G, Kershenobich D, Terrazas LI, Escobedo G. Th2-associated alternative Kupffer cell activation promotes liver fibrosis without inducing local inflammation. Int J Biol Sci 2011; 7: 1273-1286 [PMID: 22110380 DOI: 10.7150/ijbs.7.1273]
50. Vollmar B, Siegmund S, Richter S, Menger MD. Microvascular consequences of Kupffer cell modulation in rat liver fibrogenesis. J Pathol 1999; 189: 85-91 [PMID: 10451493]
51. Friedman SL, Arthur MJ. Activation of cultured rat hepatic lipocytes by Kupffer cell conditioned medium. Direct enhancement of matrix synthesis and stimulation of cell proliferation via induction of platelet-derived growth factor receptors. J Clin Invest 1989; 84: 1780-1785 [PMID: 2556445 DOI: 10.1172/JCI114362]
52. Matsuoka M, Zhang MY, Tsukamoto H. Sensitization of hepatic lipocytes by high-fat diet to stimulatory effects of Kupffer cell-derived factors: implication in alcoholic liver fibrogenesis. Hepatology 1990; 11: 173-182 [PMID: 2307396 DOI: 10.1002/hep.1840110204]
53. Matsuoka M, Tsukamoto H. Stimulation of hepatic lipocyte collagen production by Kupffer cell-derived transforming growth factor beta: implication for a pathogenetic role in alcoholic liver fibrogenesis. Hepatology 1990; 11: 599-605 [PMID: 2328954]
54. Deaciuc IV, Spitzer JJ. Hepatic sinusoidal endothelial cell in alcoholemia and endotoxemia. Alcohol Clin Exp Res 1996; 20: 607-614 [PMID: 8800375 DOI: 10.1111/j.1530-0277.1996. tb01662.x]
55. Stål P, Broomé U, Scheynius A, Befrits R, Hultcrantz R. Kupffer cell iron overload induces intercellular adhesion molecule-1 expression on hepatocytes in genetic hemochromatosis. Hepatology 1995; 21: 1308-1316 [PMID: 7737636 DOI: 10.1002/hep.1840210514]
56. Benyon RC, Hovell CJ, Da Gaça M, Jones EH, Iredale JP, Arthur MJ. Progelatinase A is produced and activated by rat hepatic stellate cells and promotes their proliferation. Hepatology 1999; 30: 977-986 [PMID: 10498650 DOI: 10.1002/ hep.510300431]
57. Canbay A, Feldstein AE, Higuchi H, Werneburg N, Grambihler A, Bronk SF, Gores GJ. Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology 2003; 38: 1188-1198 [PMID: 14578857 DOI: 10.1053/jhep.2003.50472]
58. Steib CJ, Gerbes AL, Bystron M, Winkel M, Härtl J, Roggel F, Prüfer T, Göke B, Bilzer M. Kupffer cell activation in normal and fibrotic livers increases portal pressure via thromboxane A(2). J Hepatol 2007; 47: 228-238 [PMID: 17573142 DOI: 10.1016/j.jhep.2007.03.019]
59. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-218 [PMID: 15690074 DOI: 10.1172/JCI200524282]
60. Schattenberg JM, Nagel M, Kim YO, Kohl T, Wörns MA, Zimmermann T, Schad A, Longerich T, Schuppan D, He YW, Galle PR, Schuchmann M. Increased hepatic fibrosis and JNK2-dependent liver injury in mice exhibiting hepatocytespecific deletion of cFLIP. Am J Physiol Gastrointest Liver Physiol 2012; 303: G498-G506 [PMID: 22700824 DOI: 10.1152/ ajpgi.00525]
61. Ribeiro PS, Cortez-Pinto H, Solá S, Castro RE, Ramalho RM, Baptista A, Moura MC, Camilo ME, Rodrigues CM. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol 2004; 99: 1708-1717 [PMID: 15330907 DOI: 10.1111/j.1572-0241.2004.40009.x]
62. Pianko S, Patella S, Sievert W. Alcohol consumption induces hepatocyte apoptosis in patients with chronic hepatitis C infection. J Gastroenterol Hepatol 2000; 15: 798-805 [PMID: 10937688 DOI: 10.1046/j.1440-1746.2000.02083.x]
63. Marshall A, Rushbrook S, Davies SE, Morris LS, Scott IS, Vowler SL, Coleman N, Alexander G. Relation between hepatocyte G1 arrest, impaired hepatic regeneration, and fibrosis in chronic hepatitis C virus infection. Gastroenterology 2005; 128: 33-42 [PMID: 15633121 DOI: 10.1053/ j.gastro.2004.09.076]
64. Lunz JG, Tsuji H, Nozaki I, Murase N, Demetris AJ. An inhibitor of cyclin-dependent kinase, stress-induced p21Waf-1/ Cip-1, mediates hepatocyte mito-inhibition during the evolution of cirrhosis. Hepatology 2005; 41: 1262-1271 [PMID: 15880761 DOI: 10.1002/hep.20709]
65. Chen L, Yang Z, Qiu F. Studies on hepatocyte apoptosis, proliferation and oncogene c-fos expression in carbon tetrachloride-induced cirrhotic rat liver. J Tongji Med Univ 1999; 19: 53-55 [PMID: 12840877 DOI: 10.1007/BF02895597]
66. Garcíade León Mdel C, Montfort I, Tello Montes E, López Vancell R, Olivos García A, González Canto A, Nequiz-Avendaño M, Pérez-Tamayo R. Hepatocyte production of modulators of extracellular liver matrix in normal and cirrhotic rat liver. Exp Mol Pathol 2006; 80: 97-108 [PMID: 16332368 DOI: 10.1016/j.yexmp.2005.03.008]
67. Jeong WI, Do SH, Yun HS, Song BJ, Kim SJ, Kwak WJ, Yoo SE, Park HY, Jeong KS. Hypoxia potentiates transforming growth factor-beta expression of hepatocyte during the cirrhotic condition in rat liver. Liver Int 2004; 24: 658-668 [PMID: 15566519 DOI: 10.1111/j.1478-3231.2004.0961.x]
68. Wiemann SU, Satyanarayana A, Tsahuridu M, Tillmann HL, Zender L, Klempnauer J, Flemming P, Franco S, Blasco MA, Manns MP, Rudolph KL. Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J 2002; 16: 935-942 [PMID: 12087054 DOI: 10.1096/ fj.01-0977com]
69. Martin IV, Borkham-Kamphorst E, Zok S, van Roeyen CR, Eriksson U, Boor P, Hittatiya K, Fischer HP, Wasmuth HE, Weiskirchen R, Eitner F, Floege J, Ostendorf T. Plateletderived growth factor (PDGF)-C neutralization reveals differential roles of PDGF receptors in liver and kidney fibrosis. Am J Pathol 2013; 182: 107-117 [PMID: 23141925 DOI: 10.1016/j.ajpath.2012.09.006]
70. Thieringer F, Maass T, Czochra P, Klopcic B, Conrad I, Friebe D, Schirmacher P, Lohse AW, Blessing M, Galle PR, Teufel A, Kanzler S. Spontaneous hepatic fibrosis in transgenic mice overexpressing PDGF-A. Gene 2008; 423: 23-28 [PMID: 18598744 DOI: 10.1016/j.gene.2008.05.022]
71. Cao S, Yaqoob U, Das A, Shergill U, Jagavelu K, Huebert RC, Routray C, Abdelmoneim S, Vasdev M, Leof E, Charlton M, Watts RJ, Mukhopadhyay D, Shah VH. Neuropilin-1 promotes cirrhosis of the rodent and human liver by enhancing PDGF/TGF-beta signaling in hepatic stellate cells. J Clin Invest 2010; 120: 2379-2394 [PMID: 20577048 DOI: 10.1172/ JCI41203]
72. Borkham-Kamphorst E, van Roeyen CR, Ostendorf T, Floege J, Gressner AM, Weiskirchen R. Pro-fibrogenic potential of PDGF-D in liver fibrosis. J Hepatol 2007; 46: 1064-1074 [PMID: 17397961 DOI: 10.1016/j.jhep.2007.01.029]
73. Borkham-Kamphorst E, Herrmann J, Stoll D, Treptau J, Gressner AM, Weiskirchen R. Dominant-negative soluble PDGF-beta receptor inhibits hepatic stellate cell activation and attenuates liver fibrosis. Lab Invest 2004; 84: 766-777 [PMID: 15077122 DOI: 10.1038/labinvest.3700094]
74. Pinzani M. PDGF and signal transduction in hepatic stellate cells. Front Biosci 2002; 7: d1720-d1726 [PMID: 12133817]
75. Czochra P, Klopcic B, Meyer E, Herkel J, Garcia-Lazaro JF, Thieringer F, Schirmacher P, Biesterfeld S, Galle PR, Lohse AW, Kanzler S. Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice. J Hepatol 2006; 45: 419-428 [PMID: 16842882 DOI: 10.1016/j.jhep.2006.04.010]
76. Foo NP, Lin SH, Lee YH, Wu MJ, Wang YJ. α-Lipoic acid inhibits liver fibrosis through the attenuation of ROS-triggered signaling in hepatic stellate cells activated by PDGF and TGF-β. Toxicology 2011; 282: 39-46 [PMID: 21251946 DOI: 10.1016/j.tox.2011.01.009]
77. Ogawa S, Ochi T, Shimada H, Inagaki K, Fujita I, Nii A, Moffat MA, Katragadda M, Violand BN, Arch RH, Masferrer JL. Anti-PDGF-B monoclonal antibody reduces liver fibrosis development. Hepatol Res 2010; 40: 1128-1141 [PMID: 20880061 DOI: 10.1111/j.1872-034X.2010.00718.x]
78. Kirmaz C, Terzioglu E, Topalak O, Bayrak P, Yilmaz O, Ersoz G, Sebik F. Serum transforming growth factorbeta1(TGF-beta1) in patients with cirrhosis, chronic hepatitis B and chronic hepatitis C [corrected]. Eur Cytokine Netw 2004; 15: 112-116 [PMID: 15319169]
79. Schuppan D, Krebs A, Bauer M, Hahn EG. Hepatitis C and liver fibrosis. Cell Death Differ 2003; 10 Suppl 1: S59-S67 [PMID: 12655347 DOI: 10.1038/sj.cdd.4401163]
80. Wells RG, Kruglov E, Dranoff JA. Autocrine release of TGF-beta by portal fibroblasts regulates cell growth. FEBS Lett 2004; 559: 107-110 [PMID: 14960316 DOI: 10.1016/ S0014-5793(04)00037-7]
81. Cui X, Shimizu I, Lu G, Itonaga M, Inoue H, Shono M, Tamaki K, Fukuno H, Ueno H, Ito S. Inhibitory effect of a soluble transforming growth factor beta type II receptor on the activation of rat hepatic stellate cells in primary culture. J Hepatol 2003; 39: 731-737 [PMID: 14568254 DOI: 10.1016/ S0168-8278(03)00216-2]
82. Liu X, Hu H, Yin JQ. Therapeutic strategies against TGF-beta signaling pathway in hepatic fibrosis. Liver Int 2006; 26: 8-22 [PMID: 16420505 DOI: 10.1111/j.1478-3231.2005.01192.x]
83. Cui Q, Wang Z, Jiang D, Qu L, Guo J, Li Z. HGF inhibits TGF-β1-induced myofibroblast differentiation and ECM deposition via MMP-2 in Achilles tendon in rat. Eur J Appl Physiol 2011; 111: 1457-1463 [PMID: 21165643 DOI: 10.1007/ s00421-010-1764-4]
84. Connolly MK, Bedrosian AS, Mallen-St Clair J, Mitchell AP, Ibrahim J, Stroud A, Pachter HL, Bar-Sagi D, Frey AB, Miller G. In liver fibrosis, dendritic cells govern hepatic inflammation in mice via TNF-alpha. J Clin Invest 2009; 119: 3213-3225 [PMID: 19855130 DOI: 10.1172/JCI37581]
85. Crespo J, Rivero M, Fábrega E, Cayón A, Amado JA, García-Unzeta MT, Pons-Romero F. Plasma leptin and TNF-alpha levels in chronic hepatitis C patients and their relationship to hepatic fibrosis. Dig Dis Sci 2002; 47: 1604-1610 [PMID: 12141823]
86. Saile B, Matthes N, El Armouche H, Neubauer K, Ramadori G. The bcl, NFkappaB and p53/p21WAF1 systems are involved in spontaneous apoptosis and in the anti-apoptotic effect of TGF-beta or TNF-alpha on activated hepatic stellate cells. Eur J Cell Biol 2001; 80: 554-561 [PMID: 11561906 DOI: 10.1078/0171-9335-00182]
87. Taimr P, Higuchi H, Kocova E, Rippe RA, Friedman S, Gores GJ. Activated stellate cells express the TRAIL receptor-2/ death receptor-5 and undergo TRAIL-mediated apoptosis. Hepatology 2003; 37: 87-95 [PMID: 12500193 DOI: 10.1053/ jhep.2003.50002]
88. Varela-Rey M, Fontán-Gabás L, Blanco P, López-Zabalza MJ, Iraburu MJ. Glutathione depletion is involved in the inhibition of procollagen alpha1(I) mRNA levels caused by TNF-alpha on hepatic stellate cells. Cytokine 2007; 37: 212-217 [PMID: 17485223 DOI: 10.1016/j.cyto.2007.03.013]
89. Koca SS, Bahcecioglu IH, Poyrazoglu OK, Ozercan IH, Sahin K, Ustundag B. The treatment with antibody of TNFalpha reduces the inflammation, necrosis and fibrosis in the non-alcoholic steatohepatitis induced by methionine-and choline-deficient diet. Inflammation 2008; 31: 91-98 [PMID: 18066656 DOI: 10.1007/s10753-007-9053-z]
90. Tomita K, Tamiya G, Ando S, Ohsumi K, Chiyo T, Mizutani A, Kitamura N, Toda K, Kaneko T, Horie Y, Han JY, Kato S, Shimoda M, Oike Y, Tomizawa M, Makino S, Ohkura T, Saito H, Kumagai N, Nagata H, Ishii H, Hibi T. Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of nonalcoholic steatohepatitis in mice. Gut 2006; 55: 415-424 [PMID: 16174657 DOI: 10.1136/gut.2005.071118]
91. Poynard T, Massard J, Rudler M, Varaud A, Lebray P, Moussalli J, Munteanu M, Ngo Y, Thabut D, Benhamou Y, Ratziu V. Impact of interferon-alpha treatment on liver fibrosis in patients with chronic hepatitis B: an overview of published trials. Gastroenterol Clin Biol 2009; 33: 916-922 [PMID: 19640664 DOI: 10.1016/j.gcb.2009.06.006]
92. Ogawa T, Kawada N, Ikeda K. Effect of natural interferon α on proliferation and apoptosis of hepatic stellate cells. Hepatol Int 2009; 3: 497-503 [PMID: 19669254 DOI: 10.1007/ s12072-009-9129-y]
93. Rao HY, Wei L, Wang JH, Fei R, Jiang D, Zhang Q, Chen HS, Cong X. Inhibitory effect of human interferon-beta-1a on activated rat and human hepatic stellate cells. J Gastroenterol Hepatol 2010; 25: 1777-1784 [PMID: 21039841 DOI: 10.1111/ j.1440-1746.2010.06264.x]
94. Baroni GS, D'Ambrosio L, Curto P, Casini A, Mancini R, Jezequel AM, Benedetti A. Interferon gamma decreases hepatic stellate cell activation and extracellular matrix deposition in rat liver fibrosis. Hepatology 1996; 23: 1189-1199 [PMID: 8621153 DOI: 10.1002/hep.510230538]
95. Du S, Li H, Cui Y, Yang L, Wu J, Huang H, Chen Y, Huang W, Zhang R, Yang J, Chen D, Li Y, Zhang S, Zhou J, Wei Z, Chow NT. Houttuynia cordata inhibits lipopolysaccharideinduced rapid pulmonary fibrosis by up-regulating IFN-γ and inhibiting the TGF-β1/Smad pathway. Int Immunopharmacol 2012; 13: 331-340 [PMID: 22561446 DOI: 10.1016/ j.intimp.2012.03.011]
96. Saile B, Eisenbach C, Dudas J, El-Armouche H, Ramadori G. Interferon-gamma acts proapoptotic on hepatic stellate cells (HSC) and abrogates the antiapoptotic effect of interferonalpha by an HSP70-dependant pathway. Eur J Cell Biol 2004; 83: 469-476 [PMID: 15540463 DOI: 10.1078/0171-9335-00409]
97. Gieling RG, Wallace K, Han YP. Interleukin-1 participates in the progression from liver injury to fibrosis. Am J Physiol Gastrointest Liver Physiol 2009; 296: G1324-G1331 [PMID: 19342509 DOI: 10.1152/ajpgi.90564.2008]
98. Kamari Y, Shaish A, Vax E, Shemesh S, Kandel-Kfir M, Arbel Y, Olteanu S, Barshack I, Dotan S, Voronov E, Dinarello CA, Apte RN, Harats D. Lack of interleukin-1α or interleukin-1β inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice. J Hepatol 2011; 55: 1086-1094 [PMID: 21354232 DOI: 10.1016/j.jhep.2011.01.048]
99. Mancini R, Benedetti A, Jezequel AM. An interleukin-1 receptor antagonist decreases fibrosis induced by dimethylnitrosamine in rat liver. Virchows Arch 1994; 424: 25-31 [PMID: 7981900 DOI: 10.1007/BF00197389]
100. Petrasek J, Bala S, Csak T, Lippai D, Kodys K, Menashy V, Barrieau M, Min SY, Kurt-Jones EA, Szabo G. IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. J Clin Invest 2012; 122: 3476-3489 [PMID: 22945633 DOI: 10.1172/JCI60777]
101. Du WJ, Zhen JH, Zeng ZQ, Zheng ZM, Xu Y, Qin LY, Chen SJ. Expression of interleukin-17 associated with disease progression and liver fibrosis with hepatitis B virus infection: IL-17 in HBV infection. Diagn Pathol 2013; 8: 40 [PMID: 23448394 DOI: 10.1186/1746-1596-8-40]
102. Hara M, Kono H, Furuya S, Hirayama K, Tsuchiya M, Fujii H. Interleukin-17A plays a pivotal role in cholestatic liver fibrosis in mice. J Surg Res 2013; 183: 574-582 [PMID: 23578751 DOI: 10.1016/j.jss.2013.03.025]
103. Meng F, Wang K, Aoyama T, Grivennikov SI, Paik Y, Scholten D, Cong M, Iwaisako K, Liu X, Zhang M, Osterreicher CH, Stickel F, Ley K, Brenner DA, Kisseleva T. Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology 2012; 143: 765-766. e1-3 [PMID: 22687286 DOI: 10.1053/ j.gastro.2012.05.049]
104. Chou WY, Lu CN, Lee TH, Wu CL, Hung KS, Concejero AM, Jawan B, Wang CH. Electroporative interleukin-10 gene transfer ameliorates carbon tetrachloride-induced murine liver fibrosis by MMP and TIMP modulation. Acta Pharmacol Sin 2006; 27: 469-476 [PMID: 16539848 DOI: 10.1111/ j.1745-7254.2006.00304.x]
105. Nelson DR, Lauwers GY, Lau JY, Davis GL. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology 2000; 118: 655-660 [PMID: 10734016 DOI: 10.1016/S0016-5085(00)70134-X]
106. Zhang LJ, Zheng WD, Chen YX, Huang YH, Chen ZX, Zhang SJ, Shi MN, Wang XZ. Antifibrotic effects of interleukin-10 on experimental hepatic fibrosis. Hepatogastroenterology 2007; 54: 2092-2098 [PMID: 18251166]
107. Huang YH, Shi MN, Zheng WD, Zhang LJ, Chen ZX, Wang XZ. Therapeutic effect of interleukin-10 on CCl4-induced hepatic fibrosis in rats. World J Gastroenterol 2006; 12: 1386-1391 [PMID: 16552806]
108. Kong X, Feng D, Wang H, Hong F, Bertola A, Wang FS, Gao B. Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice. Hepatology 2012; 56: 1150-1159 [PMID: 22473749 DOI: 10.1002/hep.25744]
109. Kishimoto T. IL-6: from its discovery to clinical applications. Int Immunol 2010; 22: 347-352 [PMID: 20410258 DOI: 10.1093/intimm/dxq030]
110. Kovalovich K, DeAngelis RA, Li W, Furth EE, Ciliberto G, Taub R. Increased toxin-induced liver injury and fibrosis in interleukin-6-deficient mice. Hepatology 2000; 31: 149-159 [PMID: 10613740 DOI: 10.1002/hep.510310123]
111. Nasir GA, Mohsin S, Khan M, Shams S, Ali G, Khan SN, Riazuddin S. Mesenchymal stem cells and Interleukin-6 attenuate liver fibrosis in mice. J Transl Med 2013; 11: 78 [PMID: 23531302 DOI: 10.1186/1479-5876-11-78]
112. Tarantino G, Conca P, Pasanisi F, Ariello M, Mastrolia M, Arena A, Tarantino M, Scopacasa F, Vecchione R. Could inflammatory markers help diagnose nonalcoholic steatohepatitis? Eur J Gastroenterol Hepatol 2009; 21: 504-511 [PMID: 19318968 DOI: 10.1097/MEG.0b013e3283229b40]
113. Tarantino G, Savastano S, Colao A. Hepatic steatosis, lowgrade chronic inflammation and hormone/growth factor/ adipokine imbalance. World J Gastroenterol 2010; 16: 4773-4783 [PMID: 20939105 DOI: 10.3748/wjg.v16.i38.4773]
114. Trebicka J, Anadol E, Elfimova N, Strack I, Roggendorf M, Viazov S, Wedemeyer I, Drebber U, Rockstroh J, Sauerbruch T, Dienes HP, Odenthal M. Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis. J Hepatol 2013; 58: 234-239 [PMID: 23085648 DOI: 10.1016/j.jhep.2012.10.015]
115. Zhang Z, Gao Z, Hu W, Yin S, Wang C, Zang Y, Chen J, Zhang J, Dong L. 3,3'-Diindolylmethane ameliorates experimental hepatic fibrosis via inhibiting miR-21 expression. Br J Pharmacol 2013; 170: 649-660 [PMID: 23902531 DOI: 10.1111/ bph.12323]
116. Wang B, Li W, Guo K, Xiao Y, Wang Y, Fan J. miR-181b promotes hepatic stellate cells proliferation by targeting p27 and is elevated in the serum of cirrhosis patients. Biochem Biophys Res Commun 2012; 421: 4-8 [PMID: 22446332 DOI: 10.1016/ j.bbrc.2012.03.025]
117. Iizuka M, Ogawa T, Enomoto M, Motoyama H, Yoshizato K, Ikeda K, Kawada N. Induction of microRNA-214-5p in human and rodent liver fibrosis. Fibrogenesis Tissue Repair 2012; 5: 12 [PMID: 22849305 DOI: 10.1186/1755-1536-5-12]
118. Ogawa T, Enomoto M, Fujii H, Sekiya Y, Yoshizato K, Ikeda K, Kawada N. MicroRNA-221/222 upregulation indicates the activation of stellate cells and the progression of liver fibrosis. Gut 2012; 61: 1600-1609 [PMID: 22267590 DOI: 10.1136/gutjnl-2011-300717]
119. Murakami Y, Toyoda H, Tanaka M, Kuroda M, Harada Y, Matsuda F, Tajima A, Kosaka N, Ochiya T, Shimotohno K. The progression of liver fibrosis is related with overexpression of the miR-199 and 200 families. PLoS One 2011; 6: e16081 [PMID: 21283674 DOI: 10.1371/journal.pone.0016081]
120. Roderburg C, Mollnow T, Bongaerts B, Elfimova N, Vargas Cardenas D, Berger K, Zimmermann H, Koch A, Vucur M, Luedde M, Hellerbrand C, Odenthal M, Trautwein C, Tacke F, Luedde T. Micro-RNA profiling in human serum reveals compartment-specific roles of miR-571 and miR-652 in liver cirrhosis. PLoS One 2012; 7: e32999 [PMID: 22412969 DOI: 10.1371/journal.pone.0032999]
121. Venugopal SK, Jiang J, Kim TH, Li Y, Wang SS, Torok NJ, Wu J, Zern MA. Liver fibrosis causes downregulation of miRNA-150 and miRNA-194 in hepatic stellate cells, and their overexpression causes decreased stellate cell activation. Am J Physiol Gastrointest Liver Physiol 2010; 298: G101-G106 [PMID: 19892940 DOI: 10.1152/ajpgi.00220.2009]
122. Roderburg C, Urban GW, Bettermann K, Vucur M, Zimmermann H, Schmidt S, Janssen J, Koppe C, Knolle P, Castoldi M, Tacke F, Trautwein C, Luedde T. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology 2011; 53: 209-218 [PMID: 20890893 DOI: 10.1002/ hep.23922]
123. Roderburg C, Luedde M, Vargas Cardenas D, Vucur M, Mollnow T, Zimmermann HW, Koch A, Hellerbrand C, Weiskirchen R, Frey N, Tacke F, Trautwein C, Luedde T. miR-133a mediates TGF-β-dependent derepression of collagen synthesis in hepatic stellate cells during liver fibrosis. J Hepatol 2013; 58: 736-742 [PMID: 23183523 DOI: 10.1016/ j.jhep.2012.11.022]
124. Zhang JJ, Meng XK, Dong C, Qiao JL, Zhang RF, Yue GQ, Zhong HY. Development of a new animal model of liver cirrhosis in swine. Eur Surg Res 2009; 42: 35-39 [PMID: 18987472 DOI: 10.1159/000167855]
125. Hong RT, Xu JM, Mei Q. Melatonin ameliorates experimental hepatic fibrosis induced by carbon tetrachloride in rats. World J Gastroenterol 2009; 15: 1452-1458 [PMID: 19322917 DOI: 10.3748/wjg.15.1452]
126. Wang JY, Guo JS, Li H, Liu SL, Zern MA. Inhibitory effect of glycyrrhizin on NF-kappaB binding activity in CCl4-plus ethanol-induced liver cirrhosis in rats. Liver 1998; 18: 180-185 [PMID: 9716228 DOI: 10.1111/j.1600-0676.1998.tb00147.x]
127. Karantonis HC, Gribilas G, Stamoulis I, Giaginis C, Spiliopoulou C, Kouraklis G, Demopoulos C, Theocharis SE. Platelet-activating factor involvement in thioacetamide-induced experimental liver fibrosis and cirrhosis. Dig Dis Sci 2010; 55: 276-284 [PMID: 19242794 DOI: 10.1007/s10620-009-0745-0]
128. Chen IS, Chen YC, Chou CH, Chuang RF, Sheen LY, Chiu CH. Hepatoprotection of silymarin against thioacetamideinduced chronic liver fibrosis. J Sci Food Agric 2012; 92: 1441-1447 [PMID: 22102319 DOI: 10.1002/jsfa.4723]
129. Lee MF, Liu ML, Cheng AC, Tsai ML, Ho CT, Liou WS, Pan MH. Pterostilbene inhibits dimethylnitrosamine-induced liver fibrosis in rats. Food Chem 2013; 138: 802-807 [PMID: 23411180 DOI: 10.1016/j.foodchem.2012.11.094]
130. Lee MF, Tsai ML, Sun PP, Chien LL, Cheng AC, Ma NJ, Ho CT, Pan MH. Phyto-power dietary supplement potently inhibits dimethylnitrosamine-induced liver fibrosis in rats. Food Funct 2013; 4: 470-475 [PMID: 23291610 DOI: 10.1039/ c2fo30306j]
131. Pierre S, Chevallier A, Teixeira-Clerc F, Ambolet-Camoit A, Bui LC, Bats AS, Fournet JC, Fernandez-Salguero P, Aggerbeck M, Lotersztajn S, Barouki R, Coumoul X. Aryl hydrocarbon receptor-dependent induction of liver fibrosis by dioxin. Toxicol Sci 2014; 137: 114-124 [PMID: 24154488 DOI: 10.1093/toxsci/kft236]
132. Wu J, Cheng ML, Li L, Li CX, Jiang L, Zhang Y, Ou B. [Model establishment of liver fibrosis in oral arsenic solution exposed mice]. Zhonghua Yixue Zazhi 2009; 89: 1455-1459 [PMID: 19953895]
133. Su X, Wang Y, Zhou G, Yang X, Yu R, Lin Y, Zheng C. Probucol attenuates ethanol-induced liver fibrosis in rats by inhibiting oxidative stress, extracellular matrix protein accumulation and cytokine production. Clin Exp Pharmacol Physiol 2014; 41: 73-80 [PMID: 24117782 DOI: 10.1111/1440-1681.12182]
134. Tan TC, Crawford DH, Jaskowski LA, Subramaniam VN, Clouston AD, Crane DI, Bridle KR, Anderson GJ, Fletcher LM. Excess iron modulates endoplasmic reticulum stressassociated pathways in a mouse model of alcohol and highfat diet-induced liver injury. Lab Invest 2013; 93: 1295-1312 [PMID: 24126888 DOI: 10.1038/labinvest.2013.121]
135. Kawaguchi K, Sakaida I, Tsuchiya M, Omori K, Takami T, Okita K. Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. Biochem Biophys Res Commun 2004; 315: 187-195 [PMID: 15013444 DOI: 10.1016/j.bbrc.2004.01.038]
136. Ibañez P, Solis N, Pizarro M, Aguayo G, Duarte I, Miquel JF, Accatino L, Arrese M. Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis. J Gastroenterol Hepatol 2007; 22: 846-851 [PMID: 17565640 DOI: 10.1111/j.1440-1746.2006.04700.x]
137. Mazo DF, de Oliveira MG, Pereira IV, Cogliati B, Stefano JT, de Souza GF, Rabelo F, Lima FR, Ferreira Alves VA, Carrilho FJ, de Oliveira CP. S-nitroso-N-acetylcysteine attenuates liver fibrosis in experimental nonalcoholic steatohepatitis. Drug Des Devel Ther 2013; 7: 553-563 [PMID: 23843692 DOI: 10.2147/DDDT.S43930]
138. Jia X, Naito H, Yetti H, Tamada H, Kitamori K, Hayashi Y, Wang D, Yanagiba Y, Wang J, Ikeda K, Yamori Y, Nakajima T. Dysregulated bile acid synthesis, metabolism and excretion in a high fat-cholesterol diet-induced fibrotic steatohepatitis in rats. Dig Dis Sci 2013; 58: 2212-2222 [PMID: 23824403 DOI: 10.1007/s10620-013-2747-1]
139. Yang L, Kwon J, Popov Y, Gajdos GB, Ordog T, Brekken RA, Mukhopadhyay D, Schuppan D, Bi Y, Simonetto D, Shah VH. Vascular endothelial growth factor promotes fibrosis resolution and repair in mice. Gastroenterology 2014; 146: 1339-50. e1 [PMID: 24503129 DOI: 10.1053/j.gastro.2014.01.061]
140. Wang X, Lopategi A, Ge X, Lu Y, Kitamura N, Urtasun R, Leung TM, Fiel MI, Nieto N. Osteopontin induces ductular reaction contributing to liver fibrosis. Gut 2014; Epub ahead of print [PMID: 24496779 DOI: 10.1136/gutjnl-2013-306373]
141. Liang J, Zhang B, Shen RW, Liu JB, Gao MH, Li Y, Li YY, Zhang W. Preventive effect of halofuginone on concanavalin A-induced liver fibrosis. PLoS One 2013; 8: e82232 [PMID: 24358159 DOI: 10.1371/journal.pone.0082232]
142. Wu CS, Piao XX, Piao DM, Jin YR, Li CH. Treatment of pig serum-induced rat liver fibrosis with Boschniakia rossica, oxymatrine and interferon-alpha. World J Gastroenterol 2005; 11: 122-126 [PMID: 15609410]
143. Wang BE. [Animals with liver fibrosis induced by albumin immunization]. Zhonghua Yixue Zazhi 1989; 69: 503-505, 36 [PMID: 2630026]
144. Santra A, Chowdhury A, Ghosh A, Mazumder DN. Development of an animal model of hepatic fibrosis by excretorysecretory antigen of Ascaris suum. Indian J Gastroenterol 2000; 19: 119-121 [PMID: 10918718]
145. Yang KL, Hung KC, Chang WT, Li EI. Establishment of an early liver fibrosis model by the hydrodynamics-based transfer of TGF-beta1 gene. Comp Hepatol 2007; 6: 9 [PMID: 17949486 DOI: 10.1186/1476-5926-6-9]
146. Urbanik T, Boger RJ, Longerich T, Becker K, Ehrenberg KR, Hövelmeyer N, Hahn M, Schuchmann M, Jäger D, Waisman A, Wörns MA, Schulze-Bergkamen H. Liver specific deletion of CYLDexon7/8 induces severe biliary damage, fibrosis and increases hepatocarcinogenesis in mice. J Hepatol 2012; 57: 995-1003 [PMID: 22728872 DOI: 10.1016/j.jhep.2012.06.017]
147. Sohrabpour AA, Mohamadnejad M, Malekzadeh R. Review article: the reversibility of cirrhosis. Aliment Pharmacol Ther 2012; 36: 824-832 [PMID: 22966946]
148. Gieling RG, Burt AD, Mann DA. Fibrosis and cirrhosis reversibility-molecular mechanisms. Clin Liver Dis 2008; 12: 915-937, xi [PMID: 18984474 DOI: 10.1016/j.cld.2008.07.001]
149. Arthur MJ. Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology 2002; 122: 1525-1528 [PMID: 11984538 DOI: 10.1053/gast.2002.33367]
150. Başar O, Yimaz B, Ekiz F, Giniş Z, Altinbaş A, Aktaş B, Tuna Y, Çoban S, Delibaş N, Yüksel O. Non-invasive tests in prediction of liver fibrosis in chronic hepatitis B and comparison with post-antiviral treatment results. Clin Res Hepatol Gastroenterol 2013; 37: 152-158 [PMID: 23391746 DOI: 10.1016/j.clinre.2012.07.003]
151. Berenguer M, Schuppan D. Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment. J Hepatol 2013; 58: 1028-1041 [PMID: 23262248 DOI: 10.1016/j.jhep.2012.12.014]
152. Hou G, Dick R, Brewer GJ. Improvement in dissolution of liver fibrosis in an animal model by tetrathiomolybdate. Exp Biol Med (Maywood) 2009; 234: 662-665 [PMID: 19307461 DOI: 10.3181/0811-RM-319]
153. Kim SU, Park JY, Kim do Y, Ahn SH, Choi EH, Seok JY, Lee JM, Park YN, Chon CY, Han KH. Non-invasive assessment of changes in liver fibrosis via liver stiffness measurement in patients with chronic hepatitis B: impact of antiviral treatment on fibrosis regression. Hepatol Int 2010; 4: 673-680 [PMID: 21286337 DOI: 10.1007/s12072-010-9201-7]
154. Ying C, Colonno R, De Clercq E, Neyts J. Ribavirin and mycophenolic acid markedly potentiate the anti-hepatitis B virus activity of entecavir. Antiviral Res 2007; 73: 192-196 [PMID: 17098296 DOI: 10.1016/j.antiviral.2006.10.003]
155. Degertekin B, Lok AS. Update on viral hepatitis: 2007. Curr Opin Gastroenterol 2008; 24: 306-311 [PMID: 18408458 DOI: 10.1097/MOG.0b013e3282f70285]
156. Tasci I, Mas MR, Vural SA, Deveci S, Comert B, Alcigir G, Mas N, Akay C, Bozdayi M, Yurdaydin C, Bozkaya H, Uzunalimoglu O, Isik AT, Said HM. Pegylated interferon-alpha plus taurine in treatment of rat liver fibrosis. World J Gastroenterol 2007; 13: 3237-3244 [PMID: 17589904]
157. Chávez E, Segovia J, Shibayama M, Tsutsumi V, Vergara P, Castro-Sánchez L, Salazar EP, Moreno MG, Muriel P. Antifibrotic and fibrolytic properties of celecoxib in liver damage induced by carbon tetrachloride in the rat. Liver Int 2010; 30: 969-978 [PMID: 20524983 DOI: 10.1111/ j.1478-3231.2010.02256.x]
158. Refik Mas M, Comert B, Oncu K, Vural SA, Akay C, Tasci I, Ozkomur E, Serdar M, Mas N, Alcigir G, Yener N. The effect of taurine treatment on oxidative stress in experimental liver fibrosis. Hepatol Res 2004; 28: 207-215 [PMID: 15040961 DOI: 10.1016/j.hepres.2003.11.012]
159. Wang X, Zhang R, Du J, Hu Y, Xu L, Lu J, Ye S. Vitamin E reduces hepatic fibrosis in mice with Schistosoma japonicum infection. Mol Med Rep 2012; 5: 465-468 [PMID: 22052067 DOI: 10.3892/mmr.2011.654]
160. Mohamadnejad M, Malekzadeh R, Nasseri-Moghaddam S, Hagh-Azali S, Rakhshani N, Tavangar SM, Sedaghat M, Alimohamadi SM. Impact of immunosuppressive treatment on liver fibrosis in autoimmune hepatitis. Dig Dis Sci 2005; 50: 547-551 [PMID: 15810640 DOI: 10.1007/s10620-005-2472-5]
161. Nikolaidis N, Kountouras J, Giouleme O, Tzarou V, Chatzizisi O, Patsiaoura K, Papageorgiou A, Leontsini M, Eugenidis N, Zamboulis C. Colchicine treatment of liver fibrosis. Hepatogastroenterology 2006; 53: 281-285 [PMID: 16608040]
162. Biecker E, De Gottardi A, Neef M, Unternährer M, Schneider V, Ledermann M, Sägesser H, Shaw S, Reichen J. Long-term treatment of bile duct-ligated rats with rapamycin (sirolimus) significantly attenuates liver fibrosis: analysis of the underlying mechanisms. J Pharmacol Exp Ther 2005; 313: 952-961 [PMID: 15769867 DOI: 10.1124/jpet.104.079616]
163. Neef M, Ledermann M, Saegesser H, Schneider V, Reichen J. Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis. J Hepatol 2006; 45: 786-796 [PMID: 17050028 DOI: 10.1016/j.jhep.2006.07.030]
164. Bataller R, Brenner DA. Hepatic stellate cells as a target for the treatment of liver fibrosis. Semin Liver Dis 2001; 21: 437-451 [PMID: 11586471 DOI: 10.1055/s-2001-17558]
165. Klironomos S, Notas G, Sfakianaki O, Kiagiadaki F, Xidakis C, Kouroumalis E. Octreotide modulates the effects on fibrosis of TNF-α, TGF-β and PDGF in activated rat hepatic stellate cells. Regul Pept 2014; 188: 5-12 [PMID: 24291170 DOI: 10.1016/j.regpep.2013.11.002]
166. Tao YY, Wang QL, Shen L, Fu WW, Liu CH. Salvianolic acid B inhibits hepatic stellate cell activation through transforming growth factor beta-1 signal transduction pathway in vivo and in vitro. Exp Biol Med (Maywood) 2013; 238: 1284-1296 [PMID: 24006304 DOI: 10.1177/1535370213498979]
167. Borkham-Kamphorst E, Stoll D, Gressner AM, Weiskirchen R. Antisense strategy against PDGF B-chain proves effective in preventing experimental liver fibrogenesis. Biochem Biophys Res Commun 2004; 321: 413-423 [PMID: 15358192 DOI: 10.1016/j.bbrc.2004.06.153]
168. Saile B, DiRocco P, Dudas J, El-Armouche H, Sebb H, Eisenbach C, Neubauer K, Ramadori G. IGF-I induces DNA synthesis and apoptosis in rat liver hepatic stellate cells (HSC) but DNA synthesis and proliferation in rat liver myofibroblasts (rMF). Lab Invest 2004; 84: 1037-1049 [PMID: 15156158 DOI: 10.1038/labinvest.3700116]
169. Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs 2001; 61: 2035-2063 [PMID: 11735632 DOI: 10.2165/00003495-200161140-00003]
170. Mas N, Tasci I, Comert B, Ocal R, Mas MR. Ursodeoxycholic acid treatment improves hepatocyte ultrastructure in rat liver fibrosis. World J Gastroenterol 2008; 14: 1108-1111 [PMID: 18286695 DOI: 10.3748/wjg.14.1108]
171. Pan XL, Zhao L, Li L, Li AH, Ye J, Yang L, Xu KS, Hou XH. Efficacy and safety of tauroursodeoxycholic acid in the treatment of liver cirrhosis: a double-blind randomized controlled trial. J Huazhong Univ Sci Technolog Med Sci 2013; 33: 189-194 [PMID: 23592128 DOI: 10.1007/s11596-013-1095-x]
172. Xu D, Wu Y, Liao ZX, Wang H. Protective effect of verapamil on multiple hepatotoxic factors-induced liver fibrosis in rats. Pharmacol Res 2007; 55: 280-286 [PMID: 17223571 DOI: 10.1016/j.phrs.2006.12.003]
173. Zhang SH, Wen KM, Wu W, Li WY, Zhao JN. Efficacy of HGF carried by ultrasound microbubble-cationic nanoliposomes complex for treating hepatic fibrosis in a bile duct ligation rat model, and its relationship with the diffusion-weighted MRI parameters. Clin Res Hepatol Gastroenterol 2013; 37: 602-607 [PMID: 24012221 DOI: 10.1016/ j.clinre.2013.05.011]
174. Wang ZX, Wang ZG, Ran HT, Ren JL, Zhang Y, Li Q, Zhu YF, Ao M. The treatment of liver fibrosis induced by hepatocyte growth factor-directed, ultrasound-targeted microbubble destruction in rats. Clin Imaging 2009; 33: 454-461 [PMID: 19857806 DOI: 10.1016/j.clinimag.2009.07.001]
175. Inagaki Y, Higashiyama R, Okazaki I. Treatment strategy for liver fibrosis through recruitment and differentiation of bone marrow stem/progenitor cells. Hepatol Res 2007; 37: 991-993 [PMID: 17976135 DOI: 10.1111/j.1872-034X.2007.00267.x]
176. Tsai PC, Fu TW, Chen YM, Ko TL, Chen TH, Shih YH, Hung SC, Fu YS. The therapeutic potential of human umbilical mesenchymal stem cells from Wharton's jelly in the treatment of rat liver fibrosis. Liver Transpl 2009; 15: 484-495 [PMID: 19399744 DOI: 10.1002/lt.21715]
177. Terai S, Takami T, Yamamoto N, Fujisawa K, Ishikawa T, Urata Y, Tanimoto H, Iwamoto T, Mizunaga Y, Matsuda T, Oono T, Marumoto M, Burganova G, Fernando Quintanilha L, Hidaka I, Marumoto Y, Saeki I, Uchida K, Yamasaki T, Tani K, Taura Y, Fujii Y, Nishina H, Okita K, Sakaida I. Status and prospects of liver cirrhosis treatment by using bone marrow-derived cells and mesenchymal cells. Tissue Eng Part B Rev 2014; 20: 206-210 [PMID: 24450831 DOI: 10.1089/ten. teb.2013.0527]
178. Seo KW, Sohn SY, Bhang DH, Nam MJ, Lee HW, Youn HY. Therapeutic effects of hepatocyte growth factor-overexpressing human umbilical cord blood-derived mesenchymal stem cells on liver fibrosis in rats. Cell Biol Int 2014; 38: 106-116 [PMID: 24115681 DOI: 10.1002/cbin.10186]
179. Cheng K, Mahato RI. Gene modulation for treating liver fibrosis. Crit Rev Ther Drug Carrier Syst 2007; 24: 93-146 [PMID: 17725523 DOI: 10.1615/CritRevTherDrugCarrierSyst.v24. i2.10]
180. Doh KO, Jung HK, Moon IJ, Kang HG, Park JH, Park JG. Prevention of CCl4-induced liver cirrhosis by ribbon antisense to transforming growth factor-beta1. Int J Mol Med 2008; 21: 33-39 [PMID: 18097613]
181. Nie QH, Zhu CL, Zhang YF, Yang J, Zhang JC, Gao RT. Inhibitory effect of antisense oligonucleotide targeting TIMP-2 on immune-induced liver fibrosis. Dig Dis Sci 2010; 55: 1286-1295 [PMID: 19517234 DOI: 10.1007/s10620-009-0858-5]
182. Lang Q, Liu Q, Xu N, Qian KL, Qi JH, Sun YC, Xiao L, Shi XF. The antifibrotic effects of TGF-β1 siRNA on hepatic fibrosis in rats. Biochem Biophys Res Commun 2011; 409: 448-453 [PMID: 21600192 DOI: 10.1016/j.bbrc.2011.05.023]
183. Li G, Xie Q, Shi Y, Li D, Zhang M, Jiang S, Zhou H, Lu H, Jin Y. Inhibition of connective tissue growth factor by siRNA prevents liver fibrosis in rats. J Gene Med 2006; 8: 889-900 [PMID: 16652398 DOI: 10.1002/jgm.894]
184. Park K, Hong SW, Hur W, Lee MY, Yang JA, Kim SW, Yoon SK, Hahn SK. Target specific systemic delivery of TGF-β siRNA/(PEI-SS)-g-HA complex for the treatment of liver cirrhosis. Biomaterials 2011; 32: 4951-4958 [PMID: 21481451 DOI: 10.1016/j.biomaterials.2011.03.044]
185. Chen SL, Zheng MH, Shi KQ, Yang T, Chen YP. A new strategy for treatment of liver fibrosis: letting MicroRNAs do the job. BioDrugs 2013; 27: 25-34 [PMID: 23329398 DOI: 10.1007/s40259-012-0005-2]
186. Daneshpour N, Griffin M, Collighan R, Perrie Y. Targeted delivery of a novel group of site-directed transglutaminase inhibitors to the liver using liposomes: a new approach for the potential treatment of liver fibrosis. J Drug Target 2011; 19: 624-631 [PMID: 21067461 DOI: 10.3109/1061186X.2010.531731]
187. Li F, Wang JY. Targeted delivery of drugs for liver fibrosis. Expert Opin Drug Deliv 2009; 6: 531-541 [PMID: 19413460 DOI: 10.1517/17425240902936834]
188. Luk JM, Wang X, Liu P, Wong KF, Chan KL, Tong Y, Hui CK, Lau GK, Fan ST. Traditional Chinese herbal medicines for treatment of liver fibrosis and cancer: from laboratory discovery to clinical evaluation. Liver Int 2007; 27: 879-890 [PMID: 17696925 DOI: 10.1111/j.1478-3231.2007.01527.x]
189. Feng Y, Cheung KF, Wang N, Liu P, Nagamatsu T, Tong Y. Chinese medicines as a resource for liver fibrosis treatment. Chin Med 2009; 4: 16 [PMID: 19695098 DOI: 10.1186/1749-8546-4-16]
190. Liu P, Hu YY, Liu C, Zhu DY, Xue HM, Xu ZQ, Xu LM, Liu CH, Gu HT, Zhang ZQ. Clinical observation of salvianolic acid B in treatment of liver fibrosis in chronic hepatitis B. World J Gastroenterol 2002; 8: 679-685 [PMID: 12174378]
191. Chen YW, Wu JX, Chen YW, Li DG, Lu HM. Tetrandrine inhibits activation of rat hepatic stellate cells in vitro via transforming growth factor-beta signaling. World J Gastroenterol 2005; 11: 2922-2926 [PMID: 15902729]
192. Zhang QS, Yuan RH, Zhang J, Tian GY. [Targeted glycyrrhetinic acid to receptors of hepatic stellate cells for the treatment of rat liver fibrosis: a pilot study]. Zhonghua Ganzangbing Zazhi 2004; 12: 512 [PMID: 15329226]
193. Chuang SE, Cheng AL, Lin JK, Kuo ML. Inhibition by curcumin of diethylnitrosamine-induced hepatic hyperplasia, inflammation, cellular gene products and cell-cycle-related proteins in rats. Food Chem Toxicol 2000; 38: 991-995 [PMID: 11038236 DOI: 10.1016/S0278-6915(00)00101-0]
194. Hsu YC, Lin YL, Chiu YT, Shiao MS, Lee CY, Huang YT. Antifibrotic effects of Salvia miltiorrhiza on dimethylnitrosamine-intoxicated rats. J Biomed Sci 2005; 12: 185-195 [PMID: 15864749 DOI: 10.1007/s11373-004-8167-7]
195. Wu YW, Fang HL, Lin WC. Post-treatment of Ganoderma lucidum reduced liver fibrosis induced by thioacetamide in mice. Phytother Res 2010; 24: 494-499 [PMID: 19621343 DOI: 10.1002/ptr.2949]
196. Liu P. Fuzheng huayu capsule in the treatment of liver fibrosis: clinical evidence and mechanism of action. Chin J Integr Med 2012; 18: 398-400 [PMID: 22438173 DOI: 10.1007/ s11655-012-1030-1]
197. Yao L, Yao ZM, Weng H, Zhao GP, Zhou YJ, Yu T. Effect of rat serum containing Biejiajian oral liquid on proliferation of rat hepatic stellate cells. World J Gastroenterol 2004; 10: 1911-1913 [PMID: 15222035]
198. Yao XX, Jiang SL, Tang YW, Yao DM, Yao X. Efficacy of Chinese medicine Yi-gan-kang granule in prophylaxis and treatment of liver fibrosis in rats. World J Gastroenterol 2005; 11: 2583-2590 [PMID: 15849816]
199. Ji G, Wang L, Zhang SH, Liu JW, Zheng PY, Liu T. Effect of Chinese medicine Qinggan Huoxuefang on inducing HSC apoptosis in alcoholic liver fibrosis rats. World J Gastroenterol 2006; 12: 2047-2052 [PMID: 16610055]